There is one clinical trial.

Clinical Trials

1 An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of the BBV152 in Healthy Volunteers

The study is designed to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of BBV152 vaccine formulations. A total sample size of 1125 healthy volunteers, with 375 and 750 volunteers in phase 1 and 2 studies, respectively.

NCT04471519 Covid19 SARS-CoV Infection Biological: BBV152A Biological: BBV152B Biological: BBV152C Biological: Placebo

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

No related HPO nodes (Using clinical trials)